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PRETREATMENT WITH 
3,5,3'TRIIODO-L-THYRONINE 
(T3) 
Effects on myocyte 
contractile function after 
hypotherlnic cardioplegic 
arrest and rewarming 
Circulating levels of 3,5,3'triiodo-L-thyronine ar  depressed after cardiopulmo- 
nary bypass and have been implicated to play a contributory role in the 
alterations in left ventricular function after hypothermic cardioplegic arrest 
and rewarming. The central hypothesis of the present study was that pretreat- 
ment of isolated myocytes with triiodothyronine will have a direct and 
beneficial effect on contractile performance after hypothermic cardioplegic 
arrest and rewarming. Contractile function in isolated pig left ventricular 
myocytes was examined by video microscopy after the following treatment 
protocols: (1) 37°C incubation in medium (normothermia) for 2 hours with 
triiodothyronine followed by a 2-hour normothermic incubation with no 
triiodothyronine, (2) 4 hours of normothermic incubation with no triiodothy- 
ronine, (3) normothermic ncubation for 2 hours with triiodothyronine fol- 
lowed by 2 hours of hyperkalemic, hypothermic cardioplegic arrest ([K+]: 24 
mmol/L; 4 ° C) and subsequent rewarming, and (4) normothermic incubation 
for 2 hours with no triiodothyronine followed by 2 hours of hyperkalemic, 
hypothermic cardioplegic arrest and rewarming. Two hours of normothermia 
with triiodothyronine increased myocyte contractile function by 30% compared 
with values in untreated control myocytes, and this increase persisted after a 
subsequent 2-hour incubation under normothermic conditions with no triiodo- 
thyronine. For example, myocyte velocity of shortening in triiodothyronine- 
pretreated myocytes was 84 _ 4.9/xm/sec compared with 62 _ 2.8 pm/sec in 
control myocytes (p < 0.05). Cardioplegic arrest and subsequent rewarming 
caused a significant reduction in myocyte velocity of shortening from normo. 
thermic values (37 _ 3.4/xm/sec, p < 0.05). However, in myocytes pretreated 
with triiodothyronine, myocyte contractile function was significantly higher 
after hypothermic cardioplegic arrest and rewarming (54 _ 2.5/xm/sec, p < 
0.05). In a second series of experiments, i~-adrenergic responsiveness was 
examined after pretreatment with triiodothyronine. In the presence of the 
/3-adrenergic agonist isoproterenol (25 nmol/L), myocyte contractile function 
was increased by 26% in the triiodothyronine-treated myocytes compared with 
that in untreated control myocytes. This enhanced/3-adrenergic esponsive- 
ness with triiodothyronine pretreatment persisted with subsequent exposure to 
hypothermic cardioplegic arrest and rewarming. In summary, triiodothyronine 
pretreatment caused an increase in myocyte contractile function and/3-adren- 
ergic responsiveness under normothermic conditions and after hypothermic 
cardioplegic arrest and rewarming. Thus the present study provides direct 
evidence to suggest hat preemptive treatment with triiodothyronine may 
improve left ventricular contractile performance after hypothermic cardiople- 
gic arrest and rewarming. (J THORAC CARDIOVASC SURG 1995;110:315-27) 
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he active form of thyroid hormone, 3,5,3'triiodo- 
-thyronine (T3) , which consists of two tyrosine 
residues coupled to iodine, is an essential factor in a 
wide variety of metabolic processes. Specifically, T 3 
increases the active transport of ions, modulates 
endocrine activity, and plays an essential role in 
protein synthesis. 1 In addition to these widespread 
metabolic effects, T 3 has been shown to directly 
affect left ventricular (LV) pump function. 2-9 For 
example, previous tudies have shown that T3 aug- 
ments cardiac output by increasing heart rate and 
decreasing peripheral vascular resistance (after- 
load), s Furthermore, T 3 has been shown to increase 
force production in isolated myocardial prepara- 
tions. 1° Clinical studies have reported a decreased 
circulating level of T 3 in patients with congestive 
heart failure, after myocardial infarction, and after 
cardiopulmonary b pass (CPB). 3' 6, 11-16 Specifically, 
the circulating level of T 3 falls after hypothermic 
cardioplegic arrest and rewarming and is associated 
with decreased LV pump function. 3' 6, 14 
These observations suggest hat T 3 may play a 
mechanistic role with respect to changes in LV 
function after hypothermic cardioplegic arrest and 
rewarming.3, 6 Accordingly, several clinical and ex- 
perimental studies have examined LV function with 
administration of T 3 after hypothermic cardioplegic 
arrest and rewarming. 3' 6 These previous studies 
have demonstrated that T 3 administration after hy- 
pothermic ardioplegic arrest and rewarming im- 
proves LV pump function. 3' 6 However, it remains 
unknown whether the beneficial effects that were 
observed with administration of T 3 after hypother- 
mic cardioplegic arrest were mediated by a direct 
augmentation of myocyte contractile function. Fur- 
thermore, whether treatment with T 3 before hypo- 
thermic cardioplegic arrest has a direct effect on 
myocyte contractile function with rewarming has not 
been examined. Therefore, the present study was 
done to test the central hypothesis that preemptive 
treatment with T 3 will improve myocyte contractile 
function with exposure to hypothermic cardioplegic 
arrest and rewarming. 
Hypothermic ardioplegic arrest and rewarming 
induces alterations in systemic loading conditions 
and systemic neurohormonal ctivation. 17-~9 Thus 
direct measurement of contractile performance in 
vivo after hypothermic ardioplegic arrest and re- 
warming can be problematic. This laboratory has 
successfully used isolated myocytes to examine the 
specific and direct effects of hypothermic cardiople- 
gic arrest and rewarming on contractile processes. 2°
That previous report demonstrated that hypother- 
mic cardioplegic arrest and rewarming decreased 
myocyte contractile performance and/3-adrenergic 
responsiveness, a° The use of this isolated myocyte 
model to examine contractile processes after hypo- 
thermic cardioplegic arrest and rewarming, there- 
fore, has distinct advantages. First, indices of myo- 
cyte contractile function are examined independent 
of the effects of the extracellular matrix and loading 
conditions. Second, neurohormonal influences are 
absent in this isolated myocyte system. Accordingly, 
the present study used this isolated myocyte model 
of hypothermic ardioplegic arrest and rewarming 
to examine the direct effects of pretreatment with T 3 
on myocyte contractile processes. 
Methods 
Myocyte isolation. Six pigs (Yorkshire strain, 28 kg) 
were anesthetized with isoflurane (0.5%/1.5 L/mill) and 
the lungs ventilated through anonrecirculating anesthesia 
circuit. A sternotomy was then done and the heart quickly 
extirpated and placed in an oxygenated Krebs solution. 
The region of the LV free wall comprising the bed of the 
left circumflex coronary artery was dissected free, the 
artery cannulated, and the tissue prepared for myocyte 
isolation. All animals were treated and cared for in 
accordance with the National Institutes of Health "Guide 
for the Care and Use of Laboratory Animals. ''21 
With the use of methods described by this laboratory 
previously,2O, 22, 23 Krebs solution containing collagenase 
(0.5 mg/ml, type n; 146 U/mg, Worthington, Inc.) was 
perfused through the circumflex artery. The tissue was 
then minced and triturated with 400 /xmol/L CaC12 and 
collagenase (0.5 mg/ml). After filtration of the superna- 
tant, the cells were allowed to settle and the myocyte 
pellet was resuspended in standard culture medium (me- 
dium 199; nutrient mixture F-12, 2 mmol/L Ca 2÷, Gibco 
Laboratories, Grand Island, N.Y.). Myocytes were sus- 
pended in cell culture medium to yield a final cell con- 
centration of 7000 viable myocytes per milliliter. 
Contractile function measurement. Myocytes were im- 
aged on an inverted microscope (Axiovert IM35, Zeiss 
Inc., Oberkochen, Germany) in a 2.5 ml tissue chamber 
with a thermoregulator  maintain the temperature of
the medium at 37 ° C. Myocytes were stimulated at 1 Hz 
and contractions were imaged with use of a charge- 
coupled device (GPCD60, Panasonic, Secaucus, N.J.). 
Myocyte motion signals were input through an edge 
detector system (Crescent Electronics, Sandy, Utah), con- 
verted into a voltage signal, digitized, and input to a 
computer (80286; ZBV2526, Zenith Data Systems, St. 
Joseph, Mich.) for subsequent analysis. 23 Stimulated myo- 
cytes were allowed a 5-minute stabilization period after 
which contraction data for each myocyte were recorded 
from a minimum of 20 consecutive contractions. Param- 
eters computed from the digitized contraction profiles 
included percentage shortening, peak velocity of shorten- 
ing (in micrometers per second), peak velocity of length- 
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Fig. 1. Treatment protocol used in present study. Myocytes were initially placed in standard culture 
medium alone or with 80 pmol/L T 3. After 2-hour incubation period in cell culture medium with or without 
supplementation f T3, one aliquot of cells from each group was subjected to 2 hours of hypothermic 
cardioplegic arrest, and a second aliquot from each group served as a control. In the first aliquot from each 
group, medium was carefully replaced with 2.5 ml of crystalloid cardioplegia solution ([K+]: 24 mmol/L; 
pH: 7.4; oxygen tension: >400 mm Hg). These cells were maintained at 4 ° C for 2 hours. In the other 
aliquot from each group, medium was carefully replaced with fresh cell culture medium not containing T3 
and placed at 37 ° C for the 2-hour incubation time. At the end of this 2-hour period (normothermia or
hypothermic cardioplegic arrest), myocytes were resuspended in cell medium at 37 ° C. Contractile function 
was examined at the time points designated with an X. 
ening (in micrometers per second), total contraction 
duration (in milliseconds), and time to peak contraction 
(in milliseconds). Contractile measurements were ob- 
tained only on those myocytes that maintained a long axis 
orientation perpendicular to the microscope objective 
throughout the', contraction profile. 
Experimental design. The experimental design of this 
project was developed to address two specific objectives: 
(1) to define the acute and prolonged effects of T3 
administration on myocyte contractile function under 
normothermic conditions and (2) to determine whether 
the effects of T3 on myocyte contractile performance 
persisted after exposure to hypothermic cardioplegic ar- 
rest and rewarming. The isolated myocyte suspensions 
were randomized to ensure uniform basal function char- 
acteristics. A schematic of the experimental design used to 
address these objectives is shown in Fig. 1. 
Effects of T 3 
Normothermic conditions. Aliquots of freshly isolated 
viable myocytes (2.5 ml) were randomly placed in stan- 
dard cell culture medium, and steady-state baseline myo- 
cyte contractile parameters were immediately obtained. 
Myocytes were then randomly assigned to medium with or 
without 80 pmol/L T3 (Sigma, St. Louis, Mo.), and con- 
tractile function was immediately measured in the Ts- 
treated groups. Next, myocytes were incubated at 37°C 
for 2 hours in standard culture medium with or without 
supplementation f 80 pmol/L T 3. After the 2-hour incu- 
bation period, steady-state myocyte contractile function 
was examined. The concentration of T 3 (80 pmol/L) and 
the incubation time (2 hours) were chosen on the basis of 
previous dose-response tudies (10 pmol/L to 500 pmol/L) 
and incubation studies (0 to 6 hours). From the dose- 
response studies, the effective concentration for a 50% 
response was computed to be 80 pmol/L T 3. The maxi- 
mum effects of this concentration of T 3 were observed 
after a 2-hour incubation period. Thus this concentration 
of T 3 and this incubation time were used in the present 
study. 
Hypothermic cardioplegic arrest. After a 2-hour incuba- 
tion period in cell culture medium with or without sup- 
plementation ofT3, the myocyte groups were subjected to 
the second portion of the protocol. One aliquot of card- 
iocytes from each group was subjected to 2 hours of 
hypothermic ardioplegic arrest, and a second aliquot 
from each group served as a control. In the first aliquot 
from each group, medium was carefully removed and 2.5 
ml of crystalloid cardioplegia solution ([K+]: 24 mmol/L; 
pH: 7.4; oxygen tension: >400 mm Hg) was added. These 
cells were maintained at 4°C for 2 hours. In the other 
aliquot from each group, medium was carefully removed 
and replaced with fresh cell culture medium not contain- 
ing T3 and the cells were placed at 37 ° C for the 2-hour 
incubation time. Thus these myocytes erved as a direct 
comparison to those exposed to hypothermic cardioplegic 
arrest. At the end of this 2-hour period (normothermia or
hypothermic ardioplegic arrest), myocytes were resus- 
pended in cell medium at 37 ° C, and contractile function 
was examined. 
J3-Adrenergic responsiveness: normothermia nd hypo- 
thermic cardioplegic arrest and rewarming. /3-Adren- 
ergic receptor agonists are commonly administered at the 
termination of hypothermic ardioplegic arrest and re- 
warming to augment LV pump function. It has been 
previously demonstrated that T 3 administration is associ- 
ated with alterations in /3-adrenergic receptor num- 
ber. 24-26 Therefore, to determine whether administration 
of T 3 or  exposure to hypothermic cardioplegic arrest and 
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Table I. Effects of incubation with T 3 on steady-state myocyte function 
0 hr incubation at 370 C 2 hr incubation at 37 ° C 
Percent shortening (%) 
No T3 5.3 - 0.2 4.5 _+ 0,2" 
80 pmol/L T 3 6.9 + 0.3t 5.9 + 0.3*t 
Shortening velocity (/zm/sec) 
No T3 80.9 -+ 3.9 61.9 -+ 2.8* 
80 pmol/L T 3 114.3 _+ 5.2? 83.8 -4- 4.9*? 
Lengthening velocity (/zm/sec) 
No T3 90.3 + 5.7 63.5 + 4.3* 
80 pmol/L T 3 129.3 + 8.3? 96.9 + 8.5*? 
Time to peak contraction (msec) 
No T3 223.5 + 7.6 263.1 : 10.6" 
80 pmol/L T 3 221.5 _+ 6.7 248.0 + 8.8* 
Duration of contraction (msec) 
No T3 459.5 + 14.0 511.8 -+ 20.3* 
80 pmol/L T 3 444.8 + 11.8 493.5 -4- 17.4 
Sample size 
No T 3 67 46 
80 pmol/L % 54 49 
All values presented as mean _+ SEM. 
*p < 0.05 versus 0 hours of incubation at 370 C. 
tp < 0.05 versus no T3. 
rewarming, or both, had an effect on myocyte/3-adrener- 
gic responsiveness, myocytes from each treatment proto- 
col were exposed to the/3-adrenergic agonist isoprotere- 
nol (25 nmol/L). This concentration of isoproterenol (25 
nmol/L) was previously determined by dose-response 
studies as the effective dose for maximum response for 
this isolated myocyte preparation. 22' 23 
Myocyte geometry with hypothermie ardioplegie arrest 
and rewarming. To determine whether changes in myo- 
cyte morphology (that is, cell swelling) occurred with 
hypothermic cardioplegic arrest and rewarming or with 
addition of 3?3, myocyte dimensions were measured. At 
the specific time point for each treatment protocol (Fig. 
1), an aliquot of cells was immediately placed in a fixative 
solution containing 2% paraformaldehyde and 2.5% glu- 
taraldehyde fixative (325 mOsm, pH 7.4). This fixation 
protocol has been shown previously to have no effect on 
myocyte shape or volume. 27 Fixed myocytes were imaged 
with the use of Hoffman modulation contrast optics (20× 
objective, Modulation Optics Inc., Greenvale, N.Y.), and 
the cell profiles digitized with use of an image analysis 
system (IBAS, Zeiss Inc., Kontron, Germany). From the 
digitized profiles, myocyte maximum and minimum di- 
mension and profile surface area were computed. 
Data analysis. Indices of myocyte contractile function 
for the groups treated with and without T 3 were compared 
by two-way analysis of variance (ANOVA). Similarly, 
indices of myocyte contractile function f r the normother- 
mic group and the hypothermic cardioplegic arrest and 
rewarming roup were compared by ANOVA. To deter- 
mine whether T3 influenced myocyte contractile function 
with hypothermic cardioplegic arrest and rewarming, mul- 
tiway ANOVA with interactions was done. If the ANOVA 
detected significant differences, mean separation was 
done with Bonferroni bounds. 2s For the /3-adrenergic 
response studies, myocyte contractile function at baseline 
and after/3-adrenergic stimulation was directly compared 
with use of a paired t test. To examine whether differences 
existed between/3-adrenergic esponsiveness and T 3 treat- 
ment after hypothermic cardioplegic arrest and rewarm- 
ing, a Student's t test was done. Myocyte dimensions for 
T 3 treatment and hypothermic ardioplegic arrest and 
rewarming were compared by ANOVA. Mean separation 
was done with Tukey's procedure. The numbers of myo- 
cytes in each group that were used to determine maximum 
and minimum dimension and profile surface area con- 
formed to a Gaussian distribution and allowed for routine 
parametric analysis. 2s All statistical procedures were done 
with use of the BMDP statistical software package 
(BMDP Statistical Software Inc., Los Angeles, Calif.). 
Results are presented as mean plus or minus the standard 
error of the mean (SEM). Values of p < 0.05 were 
considered to be statistically significant. 
Results 
Myocyte contractile function with T 3 
Normothermia. A high yield (>70%) of viable 
(rod shaped, quiescent in culture) myocytes was 
isolated from each pig used in this study. Baseline 
steady-state measurements of isolated myocyte con- 
tractile function after the immediate addition of 80 
pmol/L T3 are summarized in Table I. With the 
acute addition of 80 pmol/L T3, indices of myocyte 
contractile function significantly increased com- 
pared with those of myocytes not exposed to T3 
(Table I). For example, 80 pmol/L T 3 increased 
myocyte percent shortening by 30% and increased 
velocity of shortening by 41%. Thus, consistent with 
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Table II. Effects of incubation with T 3 on myocyte function with hypothermic cardioplegic arrest and 
rewarming  
2 hr incubation at 37 ~ C (matched control) * 2 hr incubation with HCA at 4 ° C? 
Percent shortening (%) 
No T 3 4.3 ± 0.3 2.8 ± 0.2:) 
80 pmol/L T3 5.5 -+ 0.3§ 3.8 ± 0.1:)§ 
Shortening velocity (p.m/sec) 
No T 3 50.9 ± 4.1 36.9 ± 3.4:) 
80 pmol/L T 3 69.2 +_ 5.8§ 53.9 _+ 2.5:)§ 
Lengthening velocity (txm/sec) 
No T 3 55.8 ± 6.6 35.9 ± 3.5:) 
80 pmol/L T 3 88.5 ± 9.3§ 53.6 ± 2.9:)§ 
Time to peak contraction (msec) 
No T 3 266.1 ± 9.8 238.9 ± 10.4 
80 pmol/L T3 267.8 ± 10.1 226.3 ± 8.4:) 
Duration of contraction (msec) 
No T3 526.1 ± 23.3 513.9 -+ 27.9 
80 pm01/L T 3 493.9 ± 24.7 443.9 ± 16.4 
Sample size 
NO T 3 34 42 
80 pmol/L T 3 41 44 
All values presented as mean -4- SEM. HCA, Hypothermic cardioplegic arrest. 
*Matched controls: 2 hours f incubation with orwithout T 3 then 2 hours with fresh medium (no T3) at 37 ° C. 
?Hypothermic cardioplegic arrest: 2 hours of incubation with orwithout T3, then 2 hours with cardioplegic solution (no T3) at 4 ° C. 
:~p < 0.05 versus 2-hour matched controls. 
§p < 0.05 versus noI"3. 
findings of a previous recent report from this labo- 
ratory, acute administration of T 3 improves indices 
of myocyte contractile function. 29 
After a 2-hour incubation at 37 ° C, myocyte con- 
tractile function showed a significant decline of 15% 
in percent shortening and 25% in velocity of short- 
ening from initial values (Table I). However, con- 
tractile function in myocytes incubated with T 3 
remained significantly higher than that in untreated 
myocytes and was equivalent to the function of 
untreated control myocytes at initial observation. 
However, no further augmentation of contractile 
performance occurred in the presence of T 3 during 
the incubation period. Thus the improvement in 
contractile performance with acute exposure to T 3 
was maintained espite the time-dependent decline 
in contractile, performance. 
Hypothermic ardioplegic arrest and rewarming. 
After the second 2-hour portion of the treatment 
protocol (either normothermic incubation in T3-free 
medium Or hypothermic incubation with T3-free 
cardioplegia solution), myocyte contractile function 
was examined in fresh medium at 37 ° C in all groups 
(Table II). In myocytes with no T 3 pretreatment, 
hypothermic cardioplegic arrest and rewarming 
caused a marked decline in indices of contractile 
performance. For example, myocyte percent short- 
ening declined by 36% and velocity of shortening by 
38%. In myocytes preincubated with T 3 before 
hypothermic ardioplegic arrest and rewarming, 
myocyte percent and velocity of shortening re- 
mained significantly higher than respective values in 
untreated myocytes (37% and 45% higher, respec- 
tively) (Table II). Contractile function for normo- 
thermic control and T3-pretreated myocytes did not 
significantly change during the 2-hour incubation 
period. 
g]-Adrenergie responsiveness: normothermia nd 
hypothermic cardioplegic arrest and rewarming. 
After the specific treatments outlined in Fig. 1, 
contractile function in myocytes from this portion of 
the study was examined at baseline and after the 
addition of the 13-adrenergic agonist isoproterenol 
(25 nmol/L), and the results are summarized in
Tables III and IV. Consistent with previous reports 
from this laboratory, myocyte contractile function 
significantly improved after the administration of 
isoproterenol.22, 3 In myocytes pretreated with T3, 
13-adrenergic responsiveness was significantly im- 
proved immediately and after a 2-hour incubation 
period compared that in untreated control myo- 
cytes. As shown in Table IV, when myocytes were 
incubated for an additional 2 hours in standard 
culture medium after the initial 2-hour incubation 
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Table III. Effects of incubation with Ts on myocyte [3-adrenergic responsiveness 
0 hr incubation plus 25 nmol/L 2 hr incubation plus 25 nmol/L 
isoproterenol at 37 ° C isoproterenol at 370 C 
Percent shortening (%) 
No T 3 10.4 _+ 0.7 9.3 _+ 1.1 
80 pmol/L T3 13.1 _+ 0.7* 12.2 _+ 0.8* 
Shortening velocity (~m/sec) 
No T 3 202.6 _+ 21.3 173.9 _4- 23.2 
80 pmol/L T 3 275.8 _+ 21.1" 256.6 _+ 32.9* 
Lengthening velocity (/xm/sec) 
No T 3 208.4 _+ 23.7 171.2 _+ 25.9 
80 pmol/L T3 269.4 _+ 31.0 275.5 _+ 36.9* 
Time to peak contraction (msec) 
No T 3 173.1 _+ 8.8 185.4 _+ 18.1 
80 pmol/L T3 174.5 _+ 7.3 190.1 _+ 11.1 
Duration of contraction (msec) 
No T 3 385.8 _+ 17.6 376.8 _+ 28.5 
80 pmol/L T3 386.3 _+ 21.4 351.6 _+ 17.5 
Sample size 
No T 3 21 13 
80 pmol/L T 3 19 16 
All values presented as mean _+ SEM. 
*p < 0.05 versus no T 3. 
with T3, the improvement i  /3-adrenergic respon- 
siveness persisted. Finally, in myocytes pretreated 
with T3, /3-adrenergic responsiveness was signifi- 
cantly greater than that in untreated myocytes after 
hypothermic ardioplegic arrest and rewarming. 
Thus T 3 treatment of myocytes caused a significant 
and persistent improvement in/3-adrenergic respon- 
siveness under normothermic conditions. More im- 
portantly, /3-adrenergic responsiveness was signifi- 
cantly increased after hypothermic cardioplegic 
arrest and rewarming in myocytes that had been 
pretreated with T 3. 
Myocyte geometry with hypothermic cardioplegic 
arrest and rewarming. Dimensions for isolated 
myocytes immediately fixed in an isosmolar solution 
after each treatment protocol are shown in Table V. 
The frequency distributions of myocyte profile sur- 
face area with normothermia, with hypothermic 
cardioplegic arrest, and after subsequent rewarming 
are shown in Fig. 2. Myocyte size did not signifi- 
cantly change in normothermic myocytes treated 
with T 3. In myocytes fixed at 4 ° C after 2 hours of 
hypothermic cardioplegic arrest, a significant reduc- 
tion in profile surface area was observed in compar- 
ison with that of normothermic matched control 
myocytes (Table V). For example, myocyte profile 
surface area decreased from 3438 _ 56 ixm 2 to 
3095 _+ 60 /xm 2 after hypothermic ardioplegic 
arrest (p < 0.05). When myocytes were rewarmed to 
37°C in standard culture medium subsequent to 2 
hours of hypothermic ardioplegic arrest, myocyte 
size significantly increased from not only cardiople- 
gic arrest values, but also from normothermic con- 
trol values. After rewarming, mean myocyte profile 
surface area increased to 4440 _ 60/xm 2(p < 0.05). 
Thus hypothermic cardioplegic arrest caused a sig- 
nificant reduction in myocyte size. Subsequent re- 
warming after hypothermic cardioplegic arrest 
caused myocyte swelling. Preincubation with T 3 had 
no effect on these changes in myocyte geometry 
under normothermic conditions or after hypother- 
mic cardioplegic arrest wi h or without rewarming. 
Discussion 
Each year in the United States alone myocardial 
preservation techniques withthe use of hypothermic 
cardioplegic arrest are used in more than 500,000 
patients. 3° However, hypothermic ardioplegic ar- 
rest with cold crystalloid potassium cardioplegia and 
subsequent rewarming has been associated with 
abnormalities in LV pump function. 17' 18, 2o Recent 
clinical and experimental studies have reported an 
improvement in LV pump function after T 3 admin- 
istration at the termination of hypothermic ar- 
dioplegic arrest and rewarming. 3' 6 However, two 
fundamental questions remained unanswered with 
respect o T 3 administration i the setting of hypo- 
thermic cardioplegic arrest and rewarming. First, it 
remained unknown whether T 3 administration had 
any direct effect on myocyte contractile performance 
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Table IV. Effects of incubation with T 3 on myocyte function with hypothermic cardioplegic arrest and 
rewarming on [3-adrenergic responsiveness 
2 hr incubation at 370 C 
plus 25 nmol/L isoproterenol 2 hr incubation with HCA at 4 ° C f  
(matched control)* plus 25 nmol/L isoproterenol 
Percent shortening (%) 
No r 3 7.7 +_ 0.7 6.8 + 0.5 
80 pmol/L T3 9.5 _+ 0.65 8.9 _+ 0.6:~ 
Shortening velocity (/xm/sec) 
No T 3 114.5 _+ 12.7 98.2 _+ 9.5 
80 pmol/L T3 175.5 _+ 16.3~ 134.5 _+ 8.3:~§ 
LcngthenJing velocity (/xm/sec) 
No T3 122.3 _+ 20.5 85.8 _+ 10.8 
80 pmol/L T a 152.3 _+ 12.1 114.9 _+ 9.95;§ 
Time to peak contraction (msec) 
No T 3 224.4 -- 17.2 205.3 _+ 11.9 
80 pmol/L T 3 181.1 _+ 12.2 184.9 _+ 8.6 
Duration of contraction (msec) 
No T 3 437.3 + 28.4 411.3 _+ 28.7 
80 pmol/L T 3 399.7 _+ 31.6 390.8 _+ 19.3 
Sample s~ze 
No T 3 16 19 
80 pmol/L T3 16 17 
All values presented as mean -+ SEM. HCA, Hypothermic ardioplegic arrest. 
*Matched controls: 2 hours of incubation with or without T 3 then 2 hours with fresh medium (no 3"3) at 37 ° C. 
?Hypothermic ardioplegic arrest: 2 hours of incubation with or without I"3, then 2 hours with cardioplegic solution (no T3) at 4 ° C. 
Sp < 0.05 versus no T 3. 
§p < 0.05 versus 2.-hour matched controls. 
Table V. Effects of T3 administration and hypothermic cardioplegic arrest and rewarming on myocyte geometry 
2 hr incubation 2 hr cardioplegic arrest 2 hr cardioplegic arrest 
at 37 ° C at 4 ° C at 4 ° C rewarmed to 370 C 
Profile surface area (/xm 2) 
No T 3 3438.7 _+ 55.9 3094.9 + 59.8* 4439.7 + 59.8*? 
80 pmol/L T 3 3668.5 + 55.7 3231.2 -- 62.2* 4452.8 _+ 52.8*? 
Maximum ,dimension (/xm z) 
No T 3 161.8 _+ 1.6 118.8 --- 1.7" 176.5 +_ 1.5"? 
80 pmol/L T 3 167.9 _+ 1.6 124.3 --- 1.4" 170.0 _+ 1.37~ 
Minimum dimension (/xm 2) 
No T 3 25.5 _+ 0.3 28.6 +-- 0.5* 30.2 _+ 0.3* 
80 pmol/L T 3 25.8 _+ 0.3 28.6 ___ 0.5* 30.4 _+ 0.3*? 
Sample size 
No T 3 410 285 449 
80 pmol/L T 3 395 294 533 
All values presented as mean +- SEM. 
*p < 0.05 versus 2 hours of incubation at 37 ° C. 
tp < 0.05 versus 2 hours of incubation at 4 ° C. 
-~p < 0.05 versus no T 3. 
in the setting of hypothermic ardioplegic arrest and 
rewarming. Second, it remained unknown whether 
preemptive treatment with T3 would exert beneficial 
effects on myocyte contractile performance after hy- 
pothermic cardioplegic arrest and rewarming. 
The present study attempted to address these 
issues by examining the direct effects of T 3 pretreat- 
ment on myocyte contractile performance under 
normothermic conditions and after hypothermic 
cardioplegic arrest and rewarming. This study made 
three important observations. First, a 2-hour incu- 
bation with T 3 improved indices of isolated myocyte 
contractile function under normothermic condi- 
tions. More importantly, this improvement in myo- 
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Fig. 2. Isolated myocyte profile surface area was determined by digitizing cardiocyte profiles with 
subsequent computer analysis of results. To determine profile surface area, minimum of 300 to 500 
myocytes was measured under each of following conditions: top panel, 2 hours of normothermia; middle 
panel, 2 hours of hypothermic cardioplegic arrest (HCA); bottom panel, after resuspension a d rewarming 
(R). Leftpanels represent myocytes measured in absence of T 3. Right panels represent myocytes measured 
after T 3 preincubation. These large sample sizes allowed for Gaussian distribution (black bell-shaped curve), 
thus providing means for parametric analysis. Two hours of hyperkalemic, hypothermic cardioplegic arrest 
caused significant reduction in myocyte volume in both panels. Subsequent reperfusion and rewarming 
resulted in significant increase in myocyte volume from hypothermic cardioplegic arrest values and from 
normothermic values. Preincubation with T 3 had no effect on alterations in cell size with either 
hypothermic cardioplegic arrest or with subsequent rewarming. Results are summarized in Table V. 
cyte contractile performance persisted for 2 hours 
after removal of T3 from the myocytes. Second, 
incubation with T3 for 2 hours improved/3-adrener- 
gic responsiveness in isolated myocytes. This en- 
hanced/3-adrenergic responsiveness persisted for up 
to 2 hours after removal of T 3 from the myocytes. 
Third, myocytes exposed to T3 for 2 hours followed 
by subsequent exposure for 2 hours to hypothermic 
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cardioplegic arrest and rewarming demonstrated a 
significant improvement in myocyte contractile 
function compared with that in untreated control 
myocytes. Furthermore, the enhancement in/3-ad- 
renergic responsiveness after 2 hours of T 3 incuba- 
tion persisted[ after 2 hours of hypothermic ar- 
dioplegic arrest and rewarming. Thus this study for 
the first time provides direct evidence that pretreat- 
ment with T 3 improves myocyte contractile perfor- 
mance and/3-adrenergic responsiveness after hypo- 
thermic cardioplegic arrest and rewarming. 
Clinical and experimental studies have suggested 
an association between LV pump function and 
alterations in ,circulating levels of T3 .3' 6, 11-16 Specif- 
ically, Hamilton and associates 11reported a signifi- 
cant relationship between depressed levels of T 3 and 
alterations in LV function in patients with advanced 
congestive heart failure. In a clinical study, Wiers- 
inga, Lie, and Touber 12 reported a similar decrease 
in T 3 levels for 3 days after myocardial infarction 
with hemodynamic compromise. In an experimental 
study, Buccino and associates 31reported that the 
maximum velocity of isotonic shortening in feline 
papillary muscles varied directly with the thyroid 
state. Thus previous clinical and experimental stud- 
ies have provided evidence to suggest that T 3 may be 
an important determinant in overall LV perfor- 
mance. 2-9 Consistent with a recent report, results 
from the present study demonstrated a positive 
effect of T 3 treatment on myocyte contractile func- 
tion. 29 More important, pretreatment with T3 for 2 
hours caused a persistent improvement in myocyte 
contractile function. Thus these results suggest that 
short-term T 3 pretreatment may have prolonged 
and beneficial effects on myocyte contractile perfor- 
mance under :normothermic conditions. 
The use of [hypothermic, hyperkalemic cardiople- 
gia is the most common method of myocardial 
protection during cardiac operation. However, tran- 
sient LV dysfunction can occur in the perioperative 
setting. 17-19 Several clinical and experimental stud- 
ies have demonstrated an association between de- 
creased LV function and T 3 levels after hypothermic 
cardioplegic arrest and rewarming. 3' 6, ~6 In light of 
this association between decreased levels of T3 and 
poor LV pump function after hypothermic ar- 
dioplegic arrest and rewarming, several clinical and 
experimental ',studies have examined the effects of 
the acute administration of T 3 on global indices of 
LV function after CPB. 3' 6, 14 For example, Novitzky, 
Human, and Cooper 3 reported that in pigs treated 
with T 3, cardiac output was 30% higher than that in 
untreated control animals at the termination of 
CPB. However, a direct causal relation between T3 
and LV function after hypothermic ardioplegic 
arrest and rewarming has been difficult to establish 
in light of the associated changes that occur in 
systemic loading conditions and neurohormonal sys- 
temsJ 7-19 The present study, therefore, examined 
the direct effects of T 3 administration on myocyte 
contractile function after hypothermic cardioplegic 
arrest and rewarming. Pretreatment with T 3 for 2 
hours followed by 2 hours of hypothermic cardiople- 
gic arrest and rewarming significantly improved 
myocyte contractile function compared with that in 
myocytes with no T 3 treatment. Thus this study 
provides direct evidence that the improvement in 
LV function that was observed in previous reports 
with T 3 administration after CPB may be a result of 
a direct effect of T 3 on myocyte contractile function. 
The present study examined the potential inter- 
active effects of T 3 treatment and /3-adrenergic 
responsiveness under normothermic conditions and 
after hypothermic cardioplegic arrest and rewarm- 
ing. These studies have potential clinical relevance 
for two reasons. First, an increasing number of 
patients are seen for cardiac operation with ad- 
vanced degrees of LV dysfunction. 3° Chronic LV 
failure has been clearly associated with alterations in 
the/3-adrenergic receptor system and an associated 
reduction in /3-adrenergic responsiveness. 32-35 Sec- 
ond, the transient LV dysfunction after hypothermic 
cardioplegic arrest and rewarming is commonly 
treated with/3-adrenergic receptor agonists. 36 How- 
ever, hypothermic cardioplegic arrest and rewarming 
has been shown to cause a decrease in/3-adrenergic 
receptor density and alterations in13-adrenergic recep- 
tor transduction. 37-39 Thus therapeutic strategies 
that improve/3-adrenergic responsiveness after hy- 
pothermic ardioplegic arrest and rewarming will 
have particular clinical importance. Previous reports 
have demonstrated that T 3 acutely modulates /3- 
adrenergic receptor density and responsiveness. 24' 25 
For example, Chang and Kunos 25 demonstrated that 
acute administration of T 3 increased the chrono- 
tropic response of rat myocytes to /3-adrenergic 
stimulation. Furthermore, a recent report from this 
laboratory demonstrated that acute administration 
of T3 in a control, normothermic cardiocyte prepa- 
ration improved/3-adrenergic responsiveness. 29 The 
present study builds on these previous reports by 
demonstrating that the improvement in/3-adrener- 
gic responsiveness after T 3 administration was not 
only an acute effect, but also caused prolonged and 
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beneficial effects on myocyte /3-adrenergic respon- 
siveness after T3 removal under normothermic con- 
ditions. More important, the present study demon- 
strated that myocytes pretreated with T 3 followed by 
hypothermic cardioplegic arrest and subsequent re- 
warming exhibited enhanced /3-adrenergic respon- 
siveness compared with untreated myocytes. The 
unique findings from this portion of the present 
study suggest hat T 3 pretreatment may provide a 
novel approach in enhancing/3-adrenergic respon- 
siveness in the clinical setting of hypothermic car- 
dioplegic arrest and rewarming. 
Hypothermic, hyperkalemic ardioplegic arrest 
and rewarming has long been associated with myo- 
cardial edema. 4°'43 For example, Laks and col- 
leagues 41 reported an increase in extravascular wa- 
ter content after CPB with hemodilution and 
hypothermia in canine hearts. Weng and col- 
leagues 4° reported an increase in myocardial water 
content in isolated porcine hearts after coronary 
perfusion with cardioplegic solutions. The increase 
in myocardial water content hat occurs after hypo- 
thermic ardioplegic arrest and rewarming has been 
associated with abnormalities in LV compli- 
ance. 4°-43 However, it remained unclear from these 
previous tudies whether the increased myocardial 
water content after hypothermic cardioplegic arrest 
and rewarming was intracellular, extracellular, or 
both. 4° Previous reports have demonstrated ultra- 
structural alterations within the myocyte after CPB 
or global ischemia with subsequent reperfusion. 41
Drewnowska, Clemo, and Baumgarten 44reported 
alterations in rabbit myocyte volume regulation 
after short exposure times to hyperkalemic, hypo- 
thermic cardioplegic arrest. That study demon- 
strated that the presence of magnesium, alterations 
in chloride transport, and inhibition of the sodium/ 
potassium adenosinetriphosphatase would signifi- 
cantly influence volume regulatory processes with 
hyperkalemic hypothermic ardioplegic arrest and 
rewarming. 44 The present study demonstrated that 
myocyte profile surface area, which is directly 
proportional to myocyte volume, 45 significantly de- 
creased after hyperkalemic, hypothermic ardio- 
plegic arrest and significantly increased after subse- 
quent rewarming. Thus this study provides direct 
evidence that myocyte swelling may be a contribut- 
ing factor in the increased myocardial water content 
reported in previous in vivo studies. 
Maintenance of cell volume occurs through a 
balance among factors that contribute to osmotic 
equilibrium. These include the integrity of the sar- 
colemma and its permeability to various ions and 
membrane pumps such as the sodium/potassium 
and sodium/potassium/chloride pumps. 46 Alter- 
ations in the membrane, as with ischemia, lead to 
alterations in permeability and pump function with 
resultant cell swelling or shrinkage. Specifically, with 
cell swelling, there is an efflux of electrolytes 
through activation of potassium channels and anion 
channels, probably by an increase in intracellular 
calcium activity. 46 Whalen and associates 47 de- 
scribed alterations in sodium/potassium pump activ- 
ity and increases in sarcolemmal permeability to 
sodium and calcium after ischemia. Hyperkalemic 
cardioplegic arrest maintains the myocyte in a de- 
polarized state (more positive resting potential) and 
therefore prevents excitation/contraction coupling. 
The depolarized environment results in an influx of 
sodium into the myocyte with a resultant increase in 
intracellular calcium levels by the sodium/calcium 
exchanger. 48 Thus significant alterations in ionic 
homeostasis occur with prolonged hyperkalemic 
card ioplegic  arrest,  4°-43 which in turn cause ab- 
normalities in volume regulation with subsequent 
rewarming. In the present study, the increased 
myocyte volume observed after hypothermic ar- 
dioplegic arrest and rewarming was probably a 
result of alterations in volume regulation. In light of 
the fact that T 3 has been shown to acutely regulate 
the flux of ions, glucose, and small amino acids 
across the sarcolemma, 1' 49-51 we suspected that T 3 
may influence the changes in ionic homeostasis 
during hypothermic ardioplegic arrest and there- 
fore modulate volume regulation with subsequent 
rewarming. However, pretreatment of myocytes 
with T 3 did not significantly affect the changes in 
myocyte volume after hypothermic cardioplegic ar- 
rest and rewarming. Two important conclusions can 
be made from this portion of the study. First, 
myocyte swelling that occurs after hypothermic car- 
dioplegic arrest and rewarming indicates abnormal- 
ities in volume regulation processes, which in turn 
may be associated with abnormalities in contractile 
processes. Second, the improvement in myocyte 
contractile function that was observed after hypo- 
thermic cardioplegic arrest and rewarming after T 3 
pretreatment was probably not a result of modula- 
tion of volume regulatory processes. 
The administration of T3 and hypothermic ar- 
dioplegic arrest and rewarming in vivo are associ- 
ated with alterations in systemic loading conditions 
and neurohormonal ctivation. 2' a7-19 In the present 
study, an in vitro system was used to eliminate the 
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influence of systemic loading conditions and neuro- 
hormonal alterations. Thus, by virtue of the experi- 
mental design, the systemic effects of T3 pretreat- 
ment could not be addressed. Second, the present 
study examined the effects of T 3 pretreatment with 
use of a fixed dosage and time interval, which were 
selected on the basis of the results of preliminary 
studies. However, it remains unclear whether the 
concentration of T 3 and the duration of treatment 
used in the present study could be applied to an in 
vivo model. In light of the findings from the present 
study that demonstrated the direct and beneficial 
effects of T 3 pretreatment i  the setting of hypother- 
mic cardiop]Iegic arrest and rewarming, future in 
vivo studies would be appropriate to address these 
issues. In a previous report, Urabe and associates 52
examined isolated myocyte contractile function in 
an unloaded state and after viscous loading of the 
myocyte. That study demonstrated intrinsic differ- 
ences in contractile performance between hypertro- 
phied and normal cardiocytes with use of this tech- 
nique. 52 In the present study the effects of T 3 
treatment on the ability of the myocyte to contract 
against an external load were not addressed. Finally, 
specific mechanisms by which pretreatment of myo- 
cytes with T 3 exerted the direct and beneficial effects 
observed on myocyte contractile performance under 
normothermic onditions and after hypothermic 
cardioplegic arrest and rewarming remain unclear. 
It is recognized that long-term administration of T 3 
(>72 hours) induces specific alterations in myocyte 
contractile protein messenger ribonucleic acid ex- 
pression and protein synthesis. 53-55 These chronic 
effects of T 3 are transduced by binding to nuclear 
receptors with resultant alterations in transcription 
rates for contractile protein transcription and trans- 
lation. 53-55 It has been demonstrated that T 3 causes 
a significant :increase in the expression of the c-myc 
protooncogene and increased mitochondrial protein 
synthesis. ~'5658 However, it is unlikely that the 
mechanisms for the acute increase in myocyte con- 
tractile function with T 3 observed in the present 
study were mediated by alterations in contractile 
protein transcription and translation. Acute admin- 
istration of T 3 can mediate intracellular regulatory 
processes within 1 hour of exposure. 56 Other acute 
effects of T 3 have been reported, which include (1) 
increased sedium channel bursting, 51'59 (2) in- 
creased Ca +e adenosinetriphosphatase activity, 6°' 61 
(3) increased adenylate cyclase activity, 62 and (4) 
altered sarcollemmal permeability to small ions, glu- 
cose, and amino acids. 1' 49-51 In the present study, T 3 
failed to prevent the volume regulatory changes 
after hypothermic cardioplegic arrest and rewarm- 
ing. Therefore the mechanism of action for the 
acute effects of T 3 on myocyte contractile processes 
is probably not caused by alterations in ion flux in 
the cardiocyte, but rather through alternative mech- 
anisms. In light of the findings from the present 
study in which T 3 had significant and prolonged 
effects on myocyte contractile performance, lucida- 
tion of the basic mechanisms responsible for these 
effects is warranted. 
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